Clinical trial
Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After…
NCT00189306 · Graceway Pharmaceuticals, LLC, Industry · Completed
Key facts
| NCT number | NCT00189306 |
|---|---|
| Title | Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream |
| Official title | An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma |
| Lead sponsor | Graceway Pharmaceuticals, LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Superficial Basal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Imiquimod 5% cream |
| Enrollment | 169 |
| Start date | Mar 1, 2001 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 10, 2010 |
| Countries | Australia, New Zealand |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: